The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes.
Saved in:
| Title: | The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes. |
|---|---|
| Authors: | Lübker C; Novo Nordisk A/S, Søborg, Denmark. cjlu@novonordisk.com., Bhavsar J; Novo Nordisk Inc., Plainsboro, NJ, USA., Duque do Vale R; Novo Nordisk A/S, Søborg, Denmark., Emerson SS; Department of Biostatistics, University of Washington, Seattle, WA, USA., Nørtoft E; Novo Nordisk A/S, Søborg, Denmark., Plutzky J; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, USA., Roberts G; Health Economics and Outcomes Research Ltd, Cardiff, UK., Tarp JM; Novo Nordisk A/S, Søborg, Denmark., Lincoff AM; Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA. |
| Source: | Advances in therapy [Adv Ther] 2025 May; Vol. 42 (5), pp. 2513-2525. Date of Electronic Publication: 2025 Mar 29. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Health Communications Inc Country of Publication: United States NLM ID: 8611864 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1865-8652 (Electronic) Linking ISSN: 0741238X NLM ISO Abbreviation: Adv Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1865-8652 |
|---|---|
| DOI: | 10.1007/s12325-025-03176-w |
